|
G |
Ache |
acetylcholinesterase |
multiple interactions increases expression |
EXP |
baicalin results in increased expression of and results in increased activity of ACHE protein baicalin results in increased expression of ACHE mRNA |
CTD |
PMID:27019979 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
ISO |
baicalin results in increased activity of AHR protein |
CTD |
PMID:17869316 PMID:26204831 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein] |
CTD |
PMID:38016618 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of ALB protein] |
CTD |
PMID:35088608 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
EXP |
baicalin inhibits the reaction [Hydrogen Peroxide affects the localization of and results in increased activity of ALOX5 protein] |
CTD |
PMID:20139896 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of ANGPT1 mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:24312512 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO EXP |
baicalin results in increased expression of BAX protein baicalin affects the reaction [Rotenone results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Rotenone results in increased expression of BAX protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX mRNA]; baicalin inhibits the reaction [Gentamicins results in increased expression of BAX protein] baicalin inhibits the reaction [Rotenone affects the expression of BAX protein] |
CTD |
PMID:21457722 PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
baicalin inhibits the reaction [Rotenone affects the expression of BCL2 protein] baicalin results in decreased expression of BCL2 protein baicalin affects the reaction [Rotenone results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Rotenone results in decreased expression of BCL2 protein] baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 mRNA]; baicalin inhibits the reaction [Gentamicins results in decreased expression of BCL2 protein] |
CTD |
PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
baicalin inhibits the reaction [Rotenone affects the expression of CASP3 protein] baicalin affects the reaction [Rotenone results in decreased activity of CASP3 protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; baicalin inhibits the reaction [Gentamicins results in increased cleavage of CASP3 protein] |
CTD |
PMID:25423838 PMID:31021006 PMID:34333357 PMID:35088608 PMID:36446982 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
baicalin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein] |
CTD |
PMID:34333357 PMID:35088608 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
baicalin results in decreased expression of CCNA2 protein |
CTD |
PMID:21457722 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression multiple interactions |
ISO |
baicalin results in increased expression of CCND1 mRNA baicalin results in decreased expression of CCND1 protein N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of CCND1 mRNA] |
CTD |
PMID:19160421 PMID:21457722 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
EXP |
baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19474275 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A1 protein]; baicalin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] baicalin results in increased expression of CYP1A1 mRNA; baicalin results in increased expression of CYP1A1 protein |
CTD |
PMID:18451504 PMID:26204831 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; 3',4'-dimethoxyflavone inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 mRNA]; resveratrol inhibits the reaction [baicalin results in increased expression of CYP1A2 protein] baicalin results in increased expression of CYP1A2 mRNA; baicalin results in increased expression of CYP1A2 protein |
CTD |
PMID:26204831 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein] |
CTD |
PMID:25625231 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [Palmitic Acid results in increased phosphorylation of ERN1 protein] |
CTD |
PMID:29031535 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Foxa2 |
forkhead box A2 |
decreases expression |
ISO |
baicalin results in decreased expression of FOXA2 mRNA; baicalin results in decreased expression of FOXA2 protein |
CTD |
PMID:32687838 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GOT1 protein] |
CTD |
PMID:15645217 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
baicalin inhibits the reaction [tert-Butylhydroperoxide results in increased activity of GPT protein] baicalin inhibits the reaction [Arsenic Trioxide results in increased activity of GPT protein] |
CTD |
PMID:15645217 PMID:35088608 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hes1 |
hes family bHLH transcription factor 1 |
increases expression multiple interactions |
ISO |
baicalin results in increased expression of HES1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HES1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192
|
|
G |
Hey1 |
hes-related family bHLH transcription factor with YRPW motif 1 |
increases expression multiple interactions |
ISO |
baicalin results in increased expression of HEY1 mRNA N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY1 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions increases expression |
ISO |
N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [baicalin results in increased expression of HEY2 mRNA] |
CTD |
PMID:19160421 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HMOX1 protein]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 mRNA]; baicalin promotes the reaction [Carbon Tetrachloride results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein] baicalin results in increased expression of HMOX1 mRNA; baicalin results in increased expression of HMOX1 protein |
CTD |
PMID:16824337 PMID:18187930 PMID:38016618 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf1a |
HNF1 homeobox A |
multiple interactions decreases expression |
ISO |
baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF1A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein] baicalin results in decreased expression of HNF1A mRNA; baicalin results in decreased expression of HNF1A protein |
CTD |
PMID:32687838 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression multiple interactions |
ISO |
baicalin results in decreased expression of HNF4A protein baicalin inhibits the reaction [HNF4A protein binds to HNF1A promoter]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A mRNA]; HNF4A protein promotes the reaction [baicalin results in decreased expression of HNF1A protein]; HNF4A protein promotes the reaction [baicalin results in decreased secretion of Hepatitis B Surface Antigens] baicalin results in decreased expression of HNF4A mRNA; baicalin results in decreased expression of HNF4A protein |
CTD |
PMID:32687838 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL1B protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]] baicalin inhibits the reaction [Rotenone results in increased expression of IL1B protein] |
CTD |
PMID:29031535 PMID:35088608 PMID:36446982 PMID:38016618 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
EXP ISO |
baicalin results in decreased expression of IL6 mRNA; baicalin results in decreased expression of IL6 protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased secretion of IL6 protein] |
CTD |
PMID:22019745 PMID:29031535 PMID:34333357 PMID:35088608 PMID:38016618 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of INS1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Itga4 |
integrin subunit alpha 4 |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein]; baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of JAK2 protein] |
CTD |
PMID:35088608 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of KDR protein] |
CTD |
PMID:36731809 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein] |
CTD |
PMID:38016618 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:34414639 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:34414639 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
decreases expression |
EXP |
baicalin results in decreased expression of MYD88 protein |
CTD |
PMID:22019745 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression |
EXP |
baicalin results in increased expression of NFKBIA protein |
CTD |
PMID:22019745 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [Palmitic Acid results in increased expression of NLRP3 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]] |
CTD |
PMID:29031535 PMID:38016618 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; mifobate inhibits the reaction [baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]] baicalin results in decreased expression of NOS2 mRNA; baicalin results in decreased expression of NOS2 protein baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] |
CTD |
PMID:18187930 PMID:22019745 PMID:24312512 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
increases activity increases expression |
ISO |
baicalin results in increased activity of NOTCH1 protein baicalin results in increased expression of NOTCH1 mRNA |
CTD |
PMID:19160421 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
Baicalin increases expression of NR1H3 mRNA and protein in foam cells |
RGD |
PMID:27389392 |
RGD:401842390 |
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases activity |
ISO |
baicalin results in increased activity of PKM protein |
CTD |
PMID:25388478 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased phosphorylation of and results in decreased activity of PPARG protein] |
CTD |
PMID:24312512 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
baicalin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:27019979 |
|
NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:122,338,370...122,389,921
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
baicalin results in decreased expression of PTGS2 mRNA; baicalin results in decreased expression of PTGS2 protein |
CTD |
PMID:22019745 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
baicalin affects the localization of and results in decreased expression of RELA protein baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of and results in increased phosphorylation of RELA protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:22019745 PMID:34333357 PMID:38016618 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] affects the localization of NFE2L2 protein; [baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL6 mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]; baicalin inhibits the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased ubiquitination of NFE2L2 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in decreased expression of KEAP1 protein]; baicalin promotes the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; baicalin promotes the reaction [[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [[baicalin co-treated with 1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of CASP1 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of IL1B protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of NLRP3 protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of PYCARD protein]]; NFE2L2 protein affects the reaction [baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased phosphorylation of RELA protein]] |
CTD |
PMID:38016618 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
baicalin promotes the reaction [Arsenic Trioxide results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:35088608 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of TEK mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
ISO |
baicalin results in decreased expression of TFAM mRNA baicalin inhibits the reaction [Rotenone results in decreased expression of TFAM mRNA] |
CTD |
PMID:36446982 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of TGFB1 mRNA]; baicalin inhibits the reaction [TGFB1 protein results in increased expression of COL1A2 mRNA] |
CTD |
PMID:19474275 PMID:34414639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
ISO |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein] |
CTD |
PMID:38016618 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression multiple interactions |
EXP ISO |
baicalin results in decreased expression of TLR4 protein baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TLR4 protein] baicalin inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 protein] |
CTD |
PMID:22019745 PMID:24312512 PMID:34333357 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
baicalin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; baicalin inhibits the reaction [[1-Methyl-4-phenylpyridinium co-treated with SNCA protein] results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF mRNA]; baicalin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] baicalin results in decreased expression of TNF mRNA; baicalin results in decreased expression of TNF protein baicalin inhibits the reaction [Paraquat results in increased expression of TNF protein] |
CTD |
PMID:16824337 PMID:18187930 PMID:22019745 PMID:34333357 PMID:35088608 PMID:38016618 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
baicalin results in increased expression of TP53 protein |
CTD |
PMID:21457722 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]; dorsomorphin inhibits the reaction [baicalin inhibits the reaction [Palmitic Acid results in increased expression of TXNIP protein]] |
CTD |
PMID:29031535 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Usp27x |
ubiquitin specific peptidase 27, X-linked |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in increased expression of USP27X protein] |
CTD |
PMID:34414639 |
|
NCBI chr X:15,123,620...15,126,855
Ensembl chr X:15,124,596...15,125,912
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
baicalin inhibits the reaction [ITGA4 protein results in increased expression of VEGFA protein] |
CTD |
PMID:36731809 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
EXP |
baicalin inhibits the reaction [Streptozocin results in decreased expression of VEGFC mRNA] |
CTD |
PMID:34414639 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
ISO |
baicalin inhibits the reaction [[Biological Products co-treated with potassium oxonate] results in increased activity of XDH protein] |
CTD |
PMID:34044073 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Abat |
4-aminobutyrate aminotransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein |
CTD |
PMID:27580383 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases response to substance decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of ABCB1A mRNA |
CTD |
PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:29950665 PMID:30701287 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression affects response to substance multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein ABCC2 protein affects the susceptibility to Dextran Sulfate ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:27580383 PMID:30701287 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression multiple interactions affects response to substance |
ISO |
Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCC3 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:27580383 PMID:29950665 PMID:30701287 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions decreases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein |
CTD |
PMID:26271895 PMID:27580383 PMID:29950665 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ABCF2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions affects response to substance decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCG2 protein affects the susceptibility to Dextran Sulfate Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA] |
CTD |
PMID:29950665 PMID:30701287 PMID:38423481 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abi1 |
abl-interactor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
|
|
G |
Acaa1a |
acetyl-CoA acyltransferase 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions increases abundance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space |
CTD RGD |
PMID:29950665 PMID:26401072 |
RGD:11555935 |
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA Dextran Sulfate results in decreased activity of ACHE protein |
CTD |
PMID:29950665 PMID:31226429 PMID:31807802 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr1 |
atypical chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983
|
|
G |
Ackr2 |
atypical chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:121,559,563...121,573,633
Ensembl chr 8:121,561,211...121,573,582
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Ackr4 |
atypical chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:104,716,067...104,723,617
|
|
G |
Acsbg2 |
acyl-CoA synthetase bubblegum family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:1,683,846...1,715,517
Ensembl chr 9:1,683,847...1,714,518
|
|
G |
Acsm1 |
acyl-CoA synthetase medium-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495
|
|
G |
Acsm3 |
acyl-CoA synthetase medium-chain family member 3 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ACSM3 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184
|
|
G |
Acss1 |
acyl-CoA synthetase short-chain family member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Actl6a |
actin-like 6A |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:115,492,374...115,508,401
Ensembl chr 2:115,492,285...115,508,401
|
|
G |
Actn1 |
actinin, alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actn2 |
actinin alpha 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622
|
|
G |
Actr2 |
actin related protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ACTR2 protein |
CTD |
PMID:35999755 |
|
NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
|
|
G |
Actr3 |
actin related protein 3 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ACTR3 protein |
CTD |
PMID:35999755 |
|
NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124
|
|
G |
Acvr1 |
activin A receptor type 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241
|
|
G |
Acy1 |
aminoacylase 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682
|
|
G |
Ada |
adenosine deaminase |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ADA protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions affects response to substance increases expression |
ISO |
ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA] ADAM17 protein affects the susceptibility to Dextran Sulfate |
CTD |
PMID:24548422 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts14 |
ADAM metallopeptidase with thrombospondin type 1 motif, 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866
|
|
G |
Adamts2 |
ADAM metallopeptidase with thrombospondin type 1 motif, 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adcy2 |
adenylate cyclase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236
|
|
G |
Adcy4 |
adenylate cyclase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108
|
|
G |
Adcy6 |
adenylate cyclase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Adcy7 |
adenylate cyclase 7 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA Dextran Sulfate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Adcyap1r1 |
ADCYAP receptor type I |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700
|
|
G |
Adgra2 |
adhesion G protein-coupled receptor A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of ADGRE1 protein flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein] |
CTD |
PMID:38583725 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adgre5 |
adhesion G protein-coupled receptor E5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638
|
|
G |
Adgrf1 |
adhesion G protein-coupled receptor F1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:17,660,930...17,711,704
|
|
G |
Adgrf5 |
adhesion G protein-coupled receptor F5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh5 |
alcohol dehydrogenase 5 (class III), chi polypeptide |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA Dextran Sulfate results in increased expression of ADM mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA |
CTD |
PMID:26271895 PMID:29950665 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA Dextran Sulfate results in decreased expression of AGT mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of AHNAK mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases response to substance |
ISO |
AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA] AHR gene mutant form results in increased susceptibility to Dextran Sulfate |
CTD |
PMID:36519841 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahsp |
alpha hemoglobin stabilizing protein |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of AHSP protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AK1 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akap12 |
A-kinase anchoring protein 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886
|
|
G |
Akap5 |
A-kinase anchoring protein 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
decreases expression increases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AKR1B1 protein Dextran Sulfate results in increased expression of AKR1B1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA |
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO EXP |
[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:26262998 PMID:36806191 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a2 |
aldehyde dehydrogenase 3 family, member A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ALDOC mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ALOX12 protein |
CTD |
PMID:35999755 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions increases activity |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA Dextran Sulfate results in increased activity of ALPL protein |
CTD |
PMID:29950665 PMID:30489199 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Angpt4 |
angiopoietin 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ano1 |
anoctamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Ano10 |
anoctamin 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
|
|
G |
Ano6 |
anoctamin 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Ano7 |
anoctamin 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323
|
|
G |
Ano9 |
anoctamin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa4 |
annexin A4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161
|
|
G |
Ap1m1 |
adaptor related protein complex 1 subunit mu 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of AP1S1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects response to substance multiple interactions |
ISO |
APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate [APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16049979 PMID:26262998 PMID:30188895 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apcs |
amyloid P component, serum |
increases expression |
ISO |
Dextran Sulfate results in increased expression of APCS protein |
CTD |
PMID:35999755 |
|
NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298
|
|
G |
Apln |
apelin |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA Dextran Sulfate results in decreased expression of APLN mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Apoa2 |
apolipoprotein A2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein |
CTD |
PMID:35999755 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of APOA4 protein [Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of APOE protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp11 |
aquaporin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725
|
|
G |
Aqp2 |
aquaporin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp8 |
aquaporin 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA Dextran Sulfate results in increased expression of AR mRNA |
CTD |
PMID:27920257 PMID:29950665 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arf3 |
ARF GTPase 3 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARF3 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arg1 |
arginase 1 |
multiple interactions decreases expression |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein] Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein |
CTD |
PMID:25026504 PMID:38164749 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap1 |
Rho GTPase activating protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARHGAP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265
|
|
G |
Arhgap20 |
Rho GTPase activating protein 20 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739
|
|
G |
Arhgap25 |
Rho GTPase activating protein 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982
|
|
G |
Arhgap40 |
Rho GTPase activating protein 40 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARHGDIA protein |
CTD |
PMID:35999755 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
increases expression multiple interactions decreases expression |
ISO |
Dextran Sulfate results in increased expression of ARHGDIB mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA Dextran Sulfate results in decreased expression of ARHGDIB protein |
CTD |
PMID:23894361 PMID:29950665 PMID:35999755 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arhgef1 |
Rho guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953
|
|
G |
Arhgef12 |
Rho guanine nucleotide exchange factor 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366
|
|
G |
Arhgef6 |
Rac/Cdc42 guanine nucleotide exchange factor 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304
|
|
G |
Arl3 |
ARF like GTPase 3 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ARL3 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820
|
|
G |
Arl9 |
ARF like GTPase 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ARL9 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARPC2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Arpc3 |
actin related protein 2/3 complex, subunit 3 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein Dextran Sulfate results in decreased expression of ARPC3 protein |
CTD |
PMID:35999755 |
|
NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651
|
|
G |
Arpc4 |
actin related protein 2/3 complex, subunit 4 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARPC4 protein |
CTD |
PMID:35999755 |
|
NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Arsb |
arylsulfatase B |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ARSB mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Asic4 |
acid sensing ion channel subunit family member 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ASS1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA] |
CTD |
PMID:27611972 PMID:31676321 PMID:35439472 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]] |
CTD |
PMID:31676321 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atic |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ATIC protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889
|
|
G |
Atp10a |
ATPase phospholipid transporting 10A (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:109,556,782...109,730,437
|
|
G |
Atp11b |
ATPase phospholipid transporting 11B (putative) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp1a4 |
ATPase Na+/K+ transporting subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:84,683,766...84,719,790
Ensembl chr13:84,683,768...84,719,687
|
|
G |
Atp1b1 |
ATPase Na+/K+ transporting subunit beta 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598 Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp2a1 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp2c2 |
ATPase secretory pathway Ca2+ transporting 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368
|
|
G |
Atp4b |
ATPase H+/K+ transporting subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:76,144,150...76,153,063
Ensembl chr16:76,144,150...76,153,063
|
|
G |
Atp6v0a2 |
ATPase H+ transporting V0 subunit a2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069
|
|
G |
Atp6v0a4 |
ATPase H+ transporting V0 subunit a4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Atp6v1e2 |
ATPase H+ transporting V1 subunit E2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626
|
|
G |
Atp6v1f |
ATPase H+ transporting V1 subunit F |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ATP6V1F mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:58,067,666...58,070,628
|
|
G |
Atp6v1g3 |
ATPase H+ transporting V1 subunit G3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:49,800,256...49,825,247
Ensembl chr13:49,794,222...49,825,247
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Atp8b2 |
ATPase phospholipid transporting 8B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883
|
|
G |
Avpr1a |
arginine vasopressin receptor 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215
|
|
G |
Avpr1b |
arginine vasopressin receptor 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792
|
|
G |
Avpr2 |
arginine vasopressin receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989
|
|
G |
Axin2 |
axin 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein] |
CTD |
PMID:31715269 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
B3gnt3 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:18,401,405...18,410,821
Ensembl chr16:18,401,405...18,410,766
|
|
G |
B3gnt7 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of B3GNT7 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170
|
|
G |
B3gnt8 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:81,135,499...81,142,263
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Banf1 |
barrier to autointegration nuclear assembly factor 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188
|
|
G |
Bank1 |
B-cell scaffold protein with ankyrin repeats 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BANK1 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein] |
CTD |
PMID:24146755 PMID:37209277 PMID:38583725 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bche |
butyrylcholinesterase |
multiple interactions decreases activity |
ISO |
[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein Dextran Sulfate results in decreased activity of BCHE protein |
CTD |
PMID:31226429 PMID:31807802 |
|
NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] |
CTD |
PMID:25449198 PMID:37209277 PMID:38583725 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl6 |
BCL6, transcription repressor |
multiple interactions |
ISO |
BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]] |
CTD |
PMID:38164749 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bcl7c |
BAF chromatin remodeling complex subunit BCL7C |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BCL7C mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein] |
CTD |
PMID:27611972 PMID:31676321 PMID:31926917 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Best1 |
bestrophin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063
|
|
G |
Bgn |
biglycan |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bin2 |
bridging integrator 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of BIN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] |
CTD |
PMID:25449198 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc6 |
baculoviral IAP repeat-containing 6 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of BIRC6 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp10 |
bone morphogenetic protein 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmpr1b |
bone morphogenetic protein receptor type 1B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368
|
|
G |
Bmpr2 |
bone morphogenetic protein receptor type 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809
|
|
G |
Bpifa1 |
BPI fold containing family A, member 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:142,627,810...142,633,553
Ensembl chr 3:142,627,810...142,633,552
|
|
G |
Bspry |
B-box and SPRY domain containing |
increases expression |
ISO |
Dextran Sulfate results in increased expression of BSPRY mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180
|
|
G |
Btf3l4 |
basic transcription factor 3-like 4 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of BTF3L4 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831
|
|
G |
C1galt1c1 |
C1GALT1-specific chaperone 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787
|
|
G |
C1qa |
complement C1q A chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qb |
complement C1q B chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C1qtnf6 |
C1q and TNF related 6 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of C1QTNF6 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412
|
|
G |
C1s |
complement C1s |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C3ar1 |
complement C3a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
C4b |
complement C4B |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein |
CTD |
PMID:35999755 |
|
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
|
|
G |
C5ar1 |
complement C5a receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cab39 |
calcium binding protein 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544
|
|
G |
Cacna1f |
calcium voltage-gated channel subunit alpha1 F |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413
|
|
G |
Cacna1s |
calcium voltage-gated channel subunit alpha1 S |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calcb |
calcitonin-related polypeptide, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calm2 |
calmodulin 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CALM2 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CALR protein |
CTD |
PMID:35999755 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Camk2g |
calcium/calmodulin-dependent protein kinase II gamma |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Capn13 |
calpain 13 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 6:22,071,845...22,166,864
Ensembl chr 6:22,071,845...22,166,850
|
|
G |
Capzb |
capping actin protein of muscle Z-line subunit beta |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAPZB protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Car3 |
carbonic anhydrase 3 |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Car4 |
carbonic anhydrase 4 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501
|
|
G |
Casp1 |
caspase 1 |
multiple interactions increases expression |
ISO EXP |
3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein] Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]] |
CTD |
PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO |
Dextran Sulfate results in increased cleavage of CASP3 protein 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein] |
CTD |
PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 PMID:37209277 PMID:38583725 PMID:38648921 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions decreases expression |
ISO |
dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein] |
CTD |
PMID:29496522 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
decreases activity multiple interactions increases activity |
ISO |
Dextran Sulfate results in decreased activity of CAT protein [Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein] |
CTD |
PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CAVIN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147
|
|
G |
Cbr1 |
carbonyl reductase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CBR1 protein |
CTD |
PMID:35999755 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr3 |
carbonyl reductase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC12 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417
|
|
G |
Ccdc124 |
coiled-coil domain containing 124 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC124 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564
|
|
G |
Ccdc13 |
coiled-coil domain containing 13 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC13 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:121,455,202...121,507,487
Ensembl chr 8:121,457,697...121,502,337
|
|
G |
Ccdc158 |
coiled-coil domain containing 158 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CCDC158 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein] |
CTD |
PMID:32272095 |
|
NCBI chr14:15,411,178...15,468,579
Ensembl chr14:15,411,163...15,468,581
|
|
G |
Ccdc88b |
coiled-coil domain containing 88B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC88B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970
|
|
G |
Ccdc9 |
coiled-coil domain containing 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC9 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:76,978,312...76,991,673
Ensembl chr 1:76,974,091...76,991,607
|
|
G |
Ccdc96 |
coiled-coil domain containing 96 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCDC96 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888
|
|
G |
Cchcr1 |
coiled-coil alpha-helical rod protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCHCR1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308
|
|
G |
Cckbr |
cholecystokinin B receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
increases secretion multiple interactions increases expression |
ISO |
Dextran Sulfate results in increased secretion of CCL11 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein] |
CTD |
PMID:21858153 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
ISO |
[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein] |
CTD |
PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 PMID:31807802 PMID:38583725 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCL27A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression multiple interactions |
ISO EXP |
Dextran Sulfate results in increased expression of CCL3 mRNA Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein] ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA] |
CTD |
PMID:19645018 PMID:30811821 PMID:33130971 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CCL7 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA] |
CTD |
PMID:19645018 PMID:29950665 PMID:32033881 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
increases expression decreases expression |
ISO |
Dextran Sulfate results in increased expression of CCL6 mRNA Dextran Sulfate results in decreased expression of CCL6 mRNA |
CTD |
PMID:19645018 PMID:35093514 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein] |
CTD |
PMID:31715269 PMID:35439472 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Ccr5 |
C-C motif chemokine receptor 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein] |
CTD |
PMID:36265525 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Ccr8 |
C-C motif chemokine receptor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629
|
|
G |
Ccrl2 |
C-C motif chemokine receptor like 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664
|
|
G |
Ccsap |
centriole, cilia and spindle-associated protein |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CCSAP mRNA |
CTD |
PMID:35093514 |
|
NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753
|
|
G |
Cd14 |
CD14 molecule |
affects response to substance multiple interactions |
ISO |
Dextran Sulfate affects the susceptibility to CD14 protein [Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA] |
CTD |
PMID:28411859 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd163 |
CD163 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD163 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd177 |
CD177 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD177 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd180 |
CD180 molecule |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CD180 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA |
CTD |
PMID:23894361 PMID:29950665 |
|
NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936
|
|
G |
Cd19 |
CD19 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD19 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975
|
|
G |
Cd200 |
Cd200 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648
|
|
G |
Cd247 |
Cd247 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd34 |
CD34 molecule |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CD34 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd4 |
Cd4 molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:157,668,878...157,695,366
Ensembl chr 4:157,668,878...157,695,191
|
|
G |
Cd44 |
CD44 molecule |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd52 |
CD52 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD52 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348
|
|
G |
Cd53 |
Cd53 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD53 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice |
RGD |
PMID:25004394 |
RGD:40925931 |
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cd72 |
Cd72 molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD72 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725
|
|
G |
Cd74 |
CD74 molecule |
increases expression decreases expression |
ISO |
Dextran Sulfate results in increased expression of CD74 mRNA Dextran Sulfate results in decreased expression of CD74 mRNA |
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd79a |
CD79a molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79A mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935
|
|
G |
Cd79b |
CD79b molecule |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CD79B mRNA |
CTD |
PMID:23894361 |
|
NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625
|
|
G |
Cd81 |
Cd81 molecule |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CD81 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein] Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein |
CTD |
PMID:29950665 PMID:38164749 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cda |
cytidine deaminase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein |
CTD |
PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions increases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein |
CTD |
PMID:34273909 PMID:36543318 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdhr2 |
cadherin-related family member 2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CDHR2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575
|
|
G |
Cdk11b |
cyclin-dependent kinase 11B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CDK11B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:166,212,761...166,238,883
Ensembl chr 5:166,212,829...166,238,876
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression multiple interactions decreases expression |
ISO |
Dextran Sulfate results in increased expression of CDX2 protein 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein] |
CTD |
PMID:29680209 PMID:38663798 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CEBPD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cel |
carboxyl ester lipase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cep131 |
centrosomal protein 131 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CEP131 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:105,346,015...105,370,380
Ensembl chr10:105,346,015...105,370,380
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA Dextran Sulfate results in decreased expression of CES1D mRNA |
CTD |
PMID:29950665 PMID:35093514 PMID:35999755 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2c |
carboxylesterase 2C |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790
|
|
G |
Ces2e |
carboxylesterase 2E |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856
|
|
G |
Cfap45 |
cilia and flagella associated protein 45 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CFAP45 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878
|
|
G |
Cfb |
complement factor B |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein |
CTD |
PMID:35999755 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfd |
complement factor D |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CFD protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Cfh |
complement factor H |
multiple interactions increases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein] Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein |
CTD |
PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755 |
|
NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838
|
|
G |
Cfl1 |
cofilin 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CFL1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cgref1 |
cell growth regulator with EF hand domain 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
|
|
G |
Chaf1a |
chromatin assembly factor 1 subunit A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHAF1A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
|
|
G |
Cherp |
calcium homeostasis endoplasmic reticulum protein |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein] |
CTD |
PMID:32272095 |
|
NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507
|
|
G |
Chmp2a |
charged multivesicular body protein 2A |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CHMP2A protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:73,660,045...73,662,894
Ensembl chr 1:73,660,046...73,662,452
|
|
G |
Chmp4b |
charged multivesicular body protein 4B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHMP4B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:143,170,859...143,211,376
Ensembl chr 3:143,170,902...143,210,844
|
|
G |
Chn2 |
chimerin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709
|
|
G |
Chrdl2 |
chordin-like 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CHRDL2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159
|
|
G |
Chrna2 |
cholinergic receptor nicotinic alpha 2 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb3 |
cholinergic receptor nicotinic beta 3 subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360
|
|
G |
Chrne |
cholinergic receptor nicotinic epsilon subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530
|
|
G |
Chst11 |
carbohydrate sulfotransferase 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CHUK protein modified form notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form] |
CTD |
PMID:25472953 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckb |
creatine kinase B |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CKB protein |
CTD |
PMID:35999755 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CKM protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clca4 |
chloride channel accessory 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CLCA4 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Clcn2 |
chloride voltage-gated channel 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:80,197,741...80,211,657
Ensembl chr11:80,198,153...80,211,657
|
|
G |
Clcn3 |
chloride voltage-gated channel 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions decreases expression increases expression |
ISO |
7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein] |
CTD |
PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn11 |
claudin 11 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions increases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein |
CTD |
PMID:26271895 PMID:29680209 PMID:36543318 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CLEC10A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Clic1 |
chloride intracellular channel 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CLIC1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein |
CTD |
PMID:35999755 |
|
NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712
|
|
G |
Cma1 |
chymase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Cmas |
cytidine monophosphate N-acetylneuraminic acid synthetase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125
|
|
G |
Cmpk1 |
cytidine/uridine monophosphate kinase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CMPK1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830
|
|
G |
Cnga4 |
cyclic nucleotide gated channel subunit alpha 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375
|
|
G |
Cnn2 |
calponin 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CNN2 protein |
CTD |
PMID:35999755 |
|
NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
decreases response to substance multiple interactions increases expression |
ISO |
CNR1 results in decreased susceptibility to Dextran Sulfate SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein] |
CTD |
PMID:15085199 PMID:27920472 PMID:30611738 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases expression affects response to substance increases response to substance |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] CNR2 protein affects the susceptibility to Dextran Sulfate CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate |
CTD |
PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Cntfr |
ciliary neurotrophic factor receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Cog1 |
component of oligomeric golgi complex 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:98,695,481...98,708,495
Ensembl chr10:98,695,423...98,709,292
|
|
G |
Col11a1 |
collagen type XI alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COL16A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA Dextran Sulfate results in decreased expression of COL1A1 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COL1A2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col22a1 |
collagen type XXII alpha 1 chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COL22A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462
|
|
G |
Col23a1 |
collagen type XXIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314
|
|
G |
Col28a1 |
collagen type XXVIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COL3A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Col6a1 |
collagen type VI alpha 1 chain |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein] Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein |
CTD |
PMID:32272095 PMID:35093514 |
|
NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597
|
|
G |
Col6a2 |
collagen type VI alpha 2 chain |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein] |
CTD |
PMID:32272095 PMID:35093514 |
|
NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564
|
|
G |
Col8a1 |
collagen type VIII alpha 1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424
|
|
G |
Coro1a |
coronin 1A |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CORO1A protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Coro1c |
coronin 1C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CORO1C protein |
CTD |
PMID:35999755 |
|
NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179
|
|
G |
Cotl1 |
coactosin-like F-actin binding protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of COTL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689
|
|
G |
Cox5b |
cytochrome c oxidase subunit 5B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of COX5B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpa1 |
carboxypeptidase A1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544
|
|
G |
Cpb2 |
carboxypeptidase B2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556
|
|
G |
Cr2 |
complement C3d receptor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CR2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235
|
|
G |
Cracd |
capping protein inhibiting regulator of actin dynamics |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CRACD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431
|
|
G |
Crhr1 |
corticotropin releasing hormone receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Crisp1 |
cysteine-rich secretory protein 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CRISP1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796
|
|
G |
Crtap |
cartilage associated protein |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein [Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein] |
CTD |
PMID:15652231 PMID:29950665 PMID:31442584 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CSF3 mRNA Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA] |
CTD |
PMID:32033881 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csf3r |
colony stimulating factor 3 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of CTNNB1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] |
CTD |
PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctps1 |
CTP synthase 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of CTPS1 protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180
|
|
G |
Ctsc |
cathepsin C |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CTSC mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Ctss |
cathepsin S |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cubn |
cubilin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:16,982,864...17,030,078
Ensembl chr11:16,982,860...17,030,046
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA] |
CTD |
PMID:25026504 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CXCL12 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl13 |
C-X-C motif chemokine ligand 13 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL13 mRNA |
CTD |
PMID:23894361 PMID:35093514 |
|
NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein] Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein |
CTD |
PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions increases expression increases secretion |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein] Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein |
CTD |
PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 PMID:31807802 PMID:34273909 PMID:34998820 PMID:36519841 More...
|
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CXCL9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBA protein |
CTD |
PMID:20637373 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein |
CTD |
PMID:20637373 PMID:23894361 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyfip1 |
cytoplasmic FMR1 interacting protein 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386
|
|
G |
Cyfip2 |
cytoplasmic FMR1 interacting protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases expression |
ISO |
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein |
CTD |
PMID:29680209 PMID:34998820 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
EXP |
[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen |
CTD |
PMID:28438436 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of CYP24A1 protein |
CTD |
PMID:38588969 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP26B1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA Dextran Sulfate results in decreased expression of CYP27B1 protein |
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Dextran Sulfate results in decreased activity of CYP2B1 protein [Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion |
CTD |
PMID:28438436 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c24 |
cytochrome P450, family 2, subfamily c, polypeptide 24 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c66 |
cytochrome P450, family 2, subfamily c, polypeptide 66 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
EXP |
Dextran Sulfate results in decreased activity of CYP2E1 protein [Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone |
CTD |
PMID:28438436 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp2r1 |
cytochrome P450, family 2, subfamily r, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein] |
CTD |
PMID:29950665 PMID:38588969 |
|
NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759
|
|
G |
Cyp2s1 |
cytochrome P450, family 2, subfamily s, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f1 |
cytochrome P450, family 4, subfamily f, polypeptide 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046
|
|
G |
Cyp4f39 |
cytochrome P450, family 4, subfamily f, polypeptide 39 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:27580383 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Dbt |
dihydrolipoamide branched chain transacylase E2 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of DBT protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609
|
|
G |
Dcn |
decorin |
multiple interactions increases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Depp1 |
DEPP autophagy regulator 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DEPP1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542
|
|
G |
Derl3 |
derlin 3 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DERL3 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of DHCR24 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhrs9 |
dehydrogenase/reductase 9 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DHRS9 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241
|
|
G |
Dhrsx |
dehydrogenase/reductase X-linked |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DHRSX mRNA |
CTD |
PMID:35093514 |
|
NCBI chr12:16,299,768...16,304,553
Ensembl chr12:16,299,808...16,304,552
|
|
G |
Dkk2 |
dickkopf WNT signaling pathway inhibitor 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA] |
CTD |
PMID:31715269 |
|
NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dmpk |
DM1 protein kinase |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593
|
|
G |
Dmrta1 |
DMRT-like family A1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of DMRTA1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433
|
|
G |
Dmwd |
DM1 locus, WD repeat containing |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DMWD mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:78,722,436...78,729,224
Ensembl chr 1:78,722,330...78,740,593
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DNAJC10 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G |
Dnm1 |
dynamin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Dnm3 |
dynamin 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108
|
|
G |
Dok2 |
docking protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402
|
|
G |
Dpep1 |
dipeptidase 1 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of DPEP1 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257
|
|
G |
Dpep2 |
dipeptidase 2 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA |
CTD |
PMID:29950665 PMID:35999755 |
|
NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Drap1 |
Dr1 associated protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DRAP1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774
|
|
G |
Dtx1 |
deltex E3 ubiquitin ligase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:35,849,647...35,880,835
Ensembl chr12:35,849,617...35,880,838
|
|
G |
Duoxa2 |
dual oxidase maturation factor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of DUOXA2 mRNA |
CTD |
PMID:23894361 |
|
NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions increases expression |
ISO |
DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate] Dextran Sulfate results in increased expression of DUSP1 mRNA |
CTD |
PMID:30844440 PMID:35093514 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Ecpas |
Ecm29 proteasome adaptor and scaffold |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ECPAS protein Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
|
|
G |
Eda |
ectodysplasin-A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172
|
|
G |
Eda2r |
ectodysplasin A2 receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268
|
|
G |
Edf1 |
endothelial differentiation-related factor 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EDF1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn2 |
endothelin 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of EDN2 protein [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA |
CTD |
PMID:16216902 PMID:29950665 |
|
NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EEF1G protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Efemp2 |
EGF containing fibulin extracellular matrix protein 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414
|
|
G |
Efhd2 |
EF-hand domain family, member D2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EFHD2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Egln2 |
egl-9 family hypoxia-inducible factor 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EGLN2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751
|
|
G |
Ehd1 |
EH-domain containing 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EHD1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212
|
|
G |
Ehd4 |
EH-domain containing 4 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein Dextran Sulfate results in decreased expression of EHD4 protein |
CTD |
PMID:35999755 |
|
NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA |
CTD |
PMID:29950665 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Ehmt2 |
euchromatic histone lysine methyltransferase 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EHMT2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
multiple interactions increases phosphorylation |
ISO |
EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein] |
CTD |
PMID:27920257 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif3a |
eukaryotic translation initiation factor 3, subunit A |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EIF5A protein |
CTD |
PMID:35999755 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EIF5B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Elane |
elastase, neutrophil expressed |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Elmo2 |
engulfment and cell motility 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185
|
|
G |
Emc2 |
ER membrane protein complex subunit 2 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 7:74,587,196...74,624,163
Ensembl chr 7:74,587,175...74,625,189
|
|
G |
Emp2 |
epithelial membrane protein 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EMP2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733
|
|
G |
Eng |
endoglin |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ENG mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of ENO1 protein |
CTD |
PMID:35999755 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336 Ensembl chr 3:160,719,951...160,731,336
|
|
G |
Eno3 |
enolase 3 |
multiple interactions decreases expression |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein] |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921
|
|
G |
Enpep |
glutamyl aminopeptidase |
multiple interactions increases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein] |
CTD |
PMID:32272095 |
|
NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of EPHX1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ereg |
epiregulin |
decreases response to substance increases expression |
ISO |
EREG protein results in decreased susceptibility to Dextran Sulfate dextran sodium sulfate increases expression of Ereg protein in colonic mucosa |
CTD RGD |
PMID:15456865 PMID:20498653 |
RGD:39457688 |
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of ERRFI1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esam |
endothelial cell adhesion molecule |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression multiple interactions |
ISO |
Dextran Sulfate results in decreased expression of ESR1 mRNA [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA |
CTD |
PMID:29950665 PMID:30270565 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA] |
CTD |
PMID:30270565 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Evl |
Enah/Vasp-like |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344
|
|
G |
Ewsr1 |
EWS RNA-binding protein 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of EWSR1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544
|
|
G |
F10 |
coagulation factor X |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F11 |
coagulation factor XI |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein |
CTD |
PMID:35999755 |
|
NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437
|
|
G |
F13a1 |
coagulation factor XIII A1 chain |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F2rl1 |
F2R like trypsin receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
|
|
G |
F5 |
coagulation factor V |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions |
ISO |
[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein |
CTD |
PMID:30611738 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions increases expression |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein] |
CTD |
PMID:26271895 PMID:32272095 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fads1 |
fatty acid desaturase 1 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FADS1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FADS2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam229a |
family with sequence similarity 229, member A |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM229A mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:141,829,716...141,830,705
Ensembl chr 5:141,828,664...141,830,705
|
|
G |
Fam50b |
family with sequence similarity 50, member B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM50B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr17:30,174,431...30,193,627
Ensembl chr17:30,174,411...30,193,615
|
|
G |
Fam98b |
family with sequence similarity 98, member B |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FAM98B mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 3:104,134,803...104,164,249
Ensembl chr 3:104,134,824...104,163,704
|
|
G |
Fau |
FAU ubiquitin like and ribosomal protein S30 fusion |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein] |
CTD |
PMID:32272095 |
|
NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742 Ensembl chr 1:203,350,189...203,351,742 Ensembl chr 6:203,350,189...203,351,742
|
|
G |
Fbln2 |
fibulin 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fbln5 |
fibulin 5 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA Dextran Sulfate results in decreased expression of FBLN5 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
|
|
G |
Fbn1 |
fibrillin 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein] |
CTD |
PMID:29950665 PMID:32272095 |
|
NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889
|
|
G |
Fbxo2 |
F-box protein 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FBXO2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355
|
|
G |
Fcer1g |
Fc epsilon receptor Ig |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443
|
|
G |
Fcgr1a |
Fc gamma receptor 1A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994
|
|
G |
Fcgr2a |
Fc gamma receptor 2A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fcsk |
fucose kinase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:38,849,130...38,874,497
Ensembl chr19:38,854,762...38,874,418
|
|
G |
Fdx1 |
ferredoxin 1 |
multiple interactions decreases expression |
ISO |
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414
|
|
G |
Fdxr |
ferredoxin reductase |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FDXR mRNA |
CTD |
PMID:35093514 |
|
NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658
|
|
G |
Fermt3 |
FERM domain containing kindlin 3 |
increases expression multiple interactions decreases expression |
ISO |
Dextran Sulfate results in increased expression of FERMT3 protein [Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein] Dextran Sulfate results in decreased expression of FERMT3 protein |
CTD |
PMID:32272095 PMID:35999755 |
|
NCBI chr 1:204,189,483...204,207,683
Ensembl chr 1:204,189,484...204,207,587
|
|
G |
Ffar2 |
free fatty acid receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033
|
|
G |
Ffar4 |
free fatty acid receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:235,873,576...235,891,597
Ensembl chr 1:235,873,576...235,891,597
|
|
G |
Fgf18 |
fibroblast growth factor 18 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions |
ISO |
Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein |
CTD |
PMID:27580383 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgfr4 |
fibroblast growth factor receptor 4 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FGFR4 mRNA |
CTD |
PMID:27580383 |
|
NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242
|
|
G |
Fgl1 |
fibrinogen-like 1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FGL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093
|
|
G |
Fhl1 |
four and a half LIM domains 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein |
CTD |
PMID:35999755 |
|
NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
decreases expression |
ISO |
Dextran Sulfate results in decreased expression of FHL2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192
|
|
G |
Fhl3 |
four and a half LIM domains 3 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FHL3 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein] |
CTD |
PMID:32272095 |
|
NCBI chr 5:136,953,947...136,961,317
Ensembl chr 5:136,950,411...136,961,317
|
|
G |
Flna |
filamin A |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein |
CTD |
PMID:35999755 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Flot2 |
flotillin 2 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of FLOT2 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein] |
CTD |
PMID:32272095 |
|
NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fmod |
fibromodulin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]] Dextran Sulfate results in increased expression of FOS mRNA |
CTD |
PMID:18687398 PMID:35093514 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxa2 |
forkhead box A2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxa3 |
forkhead box A3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein |
CTD |
PMID:35670535 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxo4 |
forkhead box O4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr X:66,385,241...66,392,115
Ensembl chr X:66,385,558...66,392,115
|
|
G |
Foxp3 |
forkhead box P3 |
increases methylation multiple interactions increases expression |
ISO EXP |
Dextran Sulfate results in increased methylation of FOXP3 gene Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene] kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA] |
CTD |
PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G |
Fpr1 |
formyl peptide receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559
|
|
G |
Fpr2 |
formyl peptide receptor 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:58,776,752...58,786,019
|
|
G |
Frat2 |
FRAT regulator of WNT signaling pathway 2 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FRAT2 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:240,654,120...240,656,449
Ensembl chr 1:240,654,137...240,656,517
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions decreases expression |
ISO |
gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein] |
CTD |
PMID:28421826 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fshr |
follicle stimulating hormone receptor |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571
|
|
G |
Fstl3 |
follistatin like 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:9,923,574...9,929,223
Ensembl chr 7:9,923,576...9,939,639
|
|
G |
Fus |
Fus RNA binding protein |
increases expression |
ISO |
Dextran Sulfate results in increased expression of FUS mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
|
|
G |
Fxyd1 |
FXYD domain-containing ion transport regulator 1 |
multiple interactions decreases expression |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA Dextran Sulfate results in decreased expression of FXYD1 mRNA |
CTD |
PMID:29950665 PMID:35093514 |
|
NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278
|
|
G |
Fxyd3 |
FXYD domain-containing ion transport regulator 3 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:86,305,531...86,312,455
|
|
G |
Fxyd4 |
FXYD domain-containing ion transport regulator 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Fzd1 |
frizzled class receptor 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
Fzd4 |
frizzled class receptor 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724
|
|
G |
Fzd5 |
frizzled class receptor 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Fzd6 |
frizzled class receptor 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776
|
|
G |
Fzd7 |
frizzled class receptor 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Fzd8 |
frizzled class receptor 8 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabbr1 |
gamma-aminobutyric acid type B receptor subunit 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944
|
|
G |
Gabra5 |
gamma-aminobutyric acid type A receptor subunit alpha 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrd |
gamma-aminobutyric acid type A receptor subunit delta |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gale |
UDP-galactose-4-epimerase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388
|
|
G |
Galk2 |
galactokinase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:113,110,030...113,233,306
|
|
G |
Galm |
galactose mutarotase |
increases expression |
ISO |
Dextran Sulfate results in increased expression of GALM mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310
|
|
G |
Galnt10 |
polypeptide N-acetylgalactosaminyltransferase 10 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013
|
|
G |
Galnt12 |
polypeptide N-acetylgalactosaminyltransferase 12 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014
|
|
G |
Galnt16 |
polypeptide N-acetylgalactosaminyltransferase 16 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705
|
|
G |
Galnt18 |
polypeptide N-acetylgalactosaminyltransferase 18 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268
|
|
G |
Galnt2 |
polypeptide N-acetylgalactosaminyltransferase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813
|
|
G |
Galnt4 |
polypeptide N-acetylgalactosaminyltransferase 4 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:33,925,229...33,927,770
|
|
G |
Galnt5 |
polypeptide N-acetylgalactosaminyltransferase 5 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:42,573,622...42,619,881
|
|
G |
Galnt6 |
polypeptide N-acetylgalactosaminyltransferase 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661
|
|
G |
Galnt7 |
polypeptide N-acetylgalactosaminyltransferase 7 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690
|
|
G |
Galntl6 |
polypeptide N-acetylgalactosaminyltransferase-like 6 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr16:31,192,880...32,443,979
Ensembl chr16:31,186,462...32,441,960
|
|
G |
Gar1 |
GAR1 ribonucleoprotein |
increases expression |
ISO |
Dextran Sulfate results in increased expression of GAR1 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524
|
|
G |
Gas8 |
growth arrest specific 8 |
increases expression |
ISO |
Dextran Sulfate results in increased expression of GAS8 mRNA |
CTD |
PMID:35093514 |
|
NCBI chr19:51,552,770...51,572,323
Ensembl chr19:51,552,816...51,572,305
|
|
G |
Gast |
gastrin |
decreases response to substance multiple interactions |
ISO |
GAST protein modified form results in decreased susceptibility to Dextran Sulfate [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA |
CTD |
PMID:16618411 PMID:29950665 |
|
NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA |
CTD |
PMID:26271895 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gbp6 |
guanylate binding protein family member 6 |
increases expression multiple interactions |
ISO |
Dextran Sulfate results in increased expression of GBP9 protein Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein] |
CTD |
PMID:32272095 |
|
NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062 Ensembl chr14:4,730,453...4,839,062
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gcnt3 |
glucosaminyl (N-acetyl) transferase 3, mucin type |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562
|
|
G |
Gdi1 |
GDP dissociation inhibitor 1 |
multiple interactions |
ISO |
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein |
CTD |
PMID:35999755 |
|
NCBI chr X:152,087,611...152,094,274
Ensembl chr X:152,087,444...152,094,272
|
|
G |
Gfpt1 |
glutamine fructose-6-phosphate transaminase 1 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471
|
|
G |
Gfpt2 |
glutamine-fructose-6-phosphate transaminase 2 |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA |
CTD |
PMID:29950665 |
|
NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329
|
|
G |
Gfus |
GDP-L-fucose synthase |
multiple interactions |
ISO |
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA |
CTD |
PMID:29950665 |
|
NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948
|
|
G |
Gfy |
golgi-associated, olfactory signaling regulator |
increases expression |
ISO |
Dextran Sulfate results in increased expression of GFY mRNA |
CTD |
PMID:35093514 |
|
NCBI chr 1:95,661,621...95,665,300
Ensembl chr 1:95,661,773...95,665,893
|
|